Acadia Pharmaceuticals (ACAD)
Develops NUPLAZID and DAYBUE for neurological and rare diseases.
$20.61
After hours−5.80 (−21.95%)
At close$26.41(+0.04%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 212 | 231 | 206 | 242 | 250 | 260 | 244 | 265 | 279 | 284 | 268 | 308 |
| Cost of revenue | 15 | 18 | 23 | 18 | 19 | 22 | 20 | 21 | 22 | 26 | 25 | 28 |
| Gross profit | 197 | 213 | 183 | 224 | 232 | 238 | 224 | 244 | 257 | 258 | 243 | 280 |
| 255 | 178 | 168 | 193 | 200 | 84 | 205 | 211 | 221 | 240 | 248 | 242 | |
| Research & development | 157 | 67 | 60 | 76 | 67 | 101 | 78 | 78 | 88 | 85 | 77 | 82 |
| 98 | 111 | 108 | 117 | 133 | 130 | 126 | 134 | 133 | 156 | 171 | 160 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 160 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | −147 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −58 | 35 | 15 | 30 | 32 | 154 | 19 | 32 | 36 | 17 | −5 | 38 |
| 6 | 5 | 6 | 7 | 7 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | |
| Interest income | 4 | 5 | 6 | 6 | 7 | 7 | 8 | 7 | 8 | 8 | 8 | 8 |
| Other non-operating income | 0 | −5 | −6 | −7 | −7 | 147 | −8 | −8 | −9 | −9 | −9 | 9 |
| Income before tax | −52 | 40 | 21 | 37 | 39 | 161 | 28 | 40 | 45 | 26 | 4 | 46 |
| Income tax expense | 13 | −6 | 4 | 4 | 6 | 17 | 9 | 14 | −27 | −247 | 0 | 15 |
| Net income from continuing operations | −65 | 46 | 17 | 33 | 33 | 144 | 19 | 27 | 72 | 274 | 4 | 32 |
| Net income | −65 | 46 | 17 | 33 | 33 | 144 | 19 | 27 | 72 | 274 | 4 | 32 |
| EPS, basic | −$0.40 | $0.28 | $0.10 | $0.20 | $0.20 | $0.86 | $0.11 | $0.16 | $0.43 | $1.62 | $0.02 | $0.18 |
| EPS, diluted | −$0.40 | $0.28 | $0.10 | $0.20 | $0.20 | $0.86 | $0.11 | $0.16 | $0.42 | $1.60 | $0.02 | $0.18 |
| Weighted average shares, basic | 164 | 165 | 165 | 166 | 166 | 166 | 167 | 168 | 169 | 169 | 171 | 172 |
| Weighted average shares, diluted | 164 | 167 | 167 | 166 | 166 | 166 | 168 | 169 | 171 | 171 | 173 | 173 |
| EBITDA | −56 | 41 | 27 | 40 | 41 | 12 | 31 | 43 | 48 | 29 | 7 | 32 |
| Depreciation & amortization | 2 | 2 | 6 | 3 | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 3 |
| EBIT | −58 | 40 | 21 | 37 | 39 | 7 | 28 | 40 | 45 | 26 | 4 | 29 |